Muhammad Usama Tariq1, Muhammad Furqan1, Hira Parveen1, Rahim Ullah1, Muhammad Muddassar2, Rahman Shah Zaib Saleem3, Vassilios Bavetsias4, Spiros Linardopoulos4,5,6, Amir Faisal7. 1. Department of Biology, Syed Babar Ali School of Science and Engineering, Lahore University of Management Sciences, Lahore, Pakistan. 2. Department of Biosciences, COMSATS University Islamabad, Islamabad, Pakistan. 3. Department of Chemistry and Chemical Engineering, Syed Babar Ali School of Science and Engineering, Lahore University of Management Sciences, Lahore, Pakistan. 4. Cancer Research UK, Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK. 5. Breast Cancer Now, Division of Breast Cancer Research, The Institute of Cancer Research, London, UK. 6. AstraZeneca, Cambridge, UK. 7. Department of Biology, Syed Babar Ali School of Science and Engineering, Lahore University of Management Sciences, Lahore, Pakistan. amir.faisal@lums.edu.pk.
Abstract
BACKGROUND: Activating mutations in the Fms-like tyrosine kinase 3 (FLT3) are among the most prevalent oncogenic mutations in acute myeloid leukaemia. Inhibitors selectively targeting FLT3 kinase have shown promising clinical activity; their success in the clinic, however, has been limited due to the emergence of acquired resistance. METHODS: CCT245718 was identified and characterised as a dual Aurora A/FLT3 inhibitor through cell-based and biochemical assays. The ability of CCT245718 to overcome TKD-mediated resistance was evaluated in a cell line-based model of drug resistance to FLT3 inhibitors. RESULTS: CCT245718 exhibits potent antiproliferative activity towards FLT3-ITD + AML cell lines and strongly binds to FLT3-ITD and TKD (D835Y) mutants in vitro. Activities of both FLT3-ITD and Aurora A are also inhibited in cells. Inhibition of FLT3 results in reduced phosphorylation of STAT5, downregulation of survivin and induction of apoptotic cell death. Moreover, CCT245718 overcomes TKD-mediated resistance in a MOLM-13-derived cell line containing FLT3 with both ITD and D835Y mutations. It also inhibits FLT3 signalling in both parental and resistant cell lines compared to FLT3-specific inhibitor MLN518, which is only active in the parental cell line. CONCLUSIONS: Our results demonstrate that CCT245718 is a potent dual FLT3/Aurora A inhibitor that can overcome TKD-mediated acquired resistance.
BACKGROUND: Activating mutations in the Fms-like tyrosine kinase 3 (FLT3) are among the most prevalent oncogenic mutations in acute myeloid leukaemia. Inhibitors selectively targeting FLT3 kinase have shown promising clinical activity; their success in the clinic, however, has been limited due to the emergence of acquired resistance. METHODS: CCT245718 was identified and characterised as a dual Aurora A/FLT3 inhibitor through cell-based and biochemical assays. The ability of CCT245718 to overcome TKD-mediated resistance was evaluated in a cell line-based model of drug resistance to FLT3 inhibitors. RESULTS: CCT245718 exhibits potent antiproliferative activity towards FLT3-ITD + AML cell lines and strongly binds to FLT3-ITD and TKD (D835Y) mutants in vitro. Activities of both FLT3-ITD and Aurora A are also inhibited in cells. Inhibition of FLT3 results in reduced phosphorylation of STAT5, downregulation of survivin and induction of apoptotic cell death. Moreover, CCT245718 overcomes TKD-mediated resistance in a MOLM-13-derived cell line containing FLT3 with both ITD and D835Y mutations. It also inhibits FLT3 signalling in both parental and resistant cell lines compared to FLT3-specific inhibitor MLN518, which is only active in the parental cell line. CONCLUSIONS: Our results demonstrate that CCT245718 is a potent dual FLT3/Aurora A inhibitor that can overcome TKD-mediated acquired resistance.
Authors: Catherine C Smith; Qi Wang; Chen-Shan Chin; Sara Salerno; Lauren E Damon; Mark J Levis; Alexander E Perl; Kevin J Travers; Susana Wang; Jeremy P Hunt; Patrick P Zarrinkar; Eric E Schadt; Andrew Kasarskis; John Kuriyan; Neil P Shah Journal: Nature Date: 2012-04-15 Impact factor: 49.962
Authors: Oliver Gautschi; Jim Heighway; Philip C Mack; Phillip R Purnell; Primo N Lara; David R Gandara Journal: Clin Cancer Res Date: 2008-03-15 Impact factor: 12.531
Authors: Weiguo Zhang; Gautam Borthakur; Chen Gao; Ye Chen; Hong Mu; Vivian R Ruvolo; Kenichi Nomoto; Nanding Zhao; Marina Konopleva; Michael Andreeff Journal: Cancer Res Date: 2016-01-28 Impact factor: 12.701
Authors: A S Moore; A Faisal; D Gonzalez de Castro; V Bavetsias; C Sun; B Atrash; M Valenti; A de Haven Brandon; S Avery; D Mair; F Mirabella; J Swansbury; A D J Pearson; P Workman; J Blagg; F I Raynaud; S A Eccles; S Linardopoulos Journal: Leukemia Date: 2012-02-22 Impact factor: 11.528